Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2009-12-04
2011-10-25
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
Reexamination Certificate
active
08044031
ABSTRACT:
A method of increasing the survival of animals and aquatic species susceptible to birnavirus infection by treating them before, during and/or after birnavirus exposure, with a chemical compound capable of inhibiting viral replication. A method of treating aquatic species to increase their survival in the presence of a virus, particularly an aquatic birnavirus, and to increase the yield of farmed fish susceptible to viral infection. The present invention provides methods for increasing survival of virally-exposed aquatic animals by administering therapeutically effective amounts of aminoghycoside compounds to aquatic animals susceptible to birnavirus infection and/or IPNV infection, particularly in fish such as salmonoid species, which are easily exposed to IPNV. The present invention also provides methods for increasing survival of virally-exposed animals by administering therapeutically effective amounts of aminoghycoside compounds to farmed animals susceptible to birnavirus infection and/or IBDV infection, particularly in poultry such as chickens, which are exposed to IBDV.
REFERENCES:
patent: 3878047 (1975-04-01), Hanka et al.
patent: 4188324 (1980-02-01), Martin
patent: 4225720 (1980-09-01), Martin
patent: 4232164 (1980-11-01), Martin
patent: 4256898 (1981-03-01), Kelly et al.
patent: RE31578 (1984-05-01), Kelly et al.
patent: 4843087 (1989-06-01), Diana
patent: 4892882 (1990-01-01), Tomita et al.
patent: 5087639 (1992-02-01), McGovren et al.
patent: 5371085 (1994-12-01), Nakano et al.
patent: 5464848 (1995-11-01), Diana et al.
patent: 5643929 (1997-07-01), Diana et al.
Roberts, “Bacterial meningitis in farmed rainbow trout Salmo gairdneri Richardson affected with chronic pancreatic necrosis”, Journal of Fish Diseases, 1978, 1, 157-164.
Bashai, “The in vivo—in vitro paradox in pneumococcal respiratory tract infections.”Journal of Antimicrobial Chemotherapy, vol. 49, pp. 433-436 (2002).
Clercq, et al., “Broad-Spectrum Antiviral Activities of Neplanocin A, 3-Deazaneplanocin A, and Their 5′-Nor Dervaitives.”Antimicrobial Agents and Chemotherapy, vol. 33, No. 8, pp. 1291-1297 (1989).
Dargan, et al., “The effect of cicloxolone sodium on the replication in cultured cells of adenovirus type 5, reovirus type 3, poliovirus type 1, two bunyaviruses and Semliki Forest Virus.”Journal of General Virology, vol. 73, pp. 407-411 (1992).
Fernandez-Larrson and Patterson, “Ribavirin is an Inhibitor of Human Immunodeficiency Virus Reverse Transcriptase.”Molecular Pharmacology, vol. 38, pp. 766-770 (1990).
Goswami, et al., “The Broad Spectrum Antiviral Agent Ribavirin Inhibits Capping of mRNA.”Biochemical and Biophysical Research Communications, vol. 89, No. 3, pp. 830-836 (1979).
Kim, et al., “Comparison of Histologic and Quantitative Techniques in Evaluation of Therapy for ExperimentalPneumocystis cariniiPneumonia.”Antimicrobial Agents and Chemotherapy, vol. 31, No. 2, pp. 197-201 (1987).
Leyseen, et al., “The Predominant Mechanism by Which Ribavirin Exerts Its Antiviral Activity In Vitro against Flaviviruses and Paramyxoviruses Is Mediated by Inhibition of IMP Dehydrogenase.”Journal of Virology, vol. 79, No. 3, pp. 1943-1947 (2005).
Miles, et al., “Inactivation of the Amidotransferase Activity of Carbamoyl Phosphate Synthetase by the Antibiotic Acivcin.”The Journal of Biological Chemistry, vol. 277, No. 6, pp. 4368-4373 (2002).
Müller, et al., “Virazole (1-β-D-Ribofuranosyl-1,2,4-Triazole-3-Carboxamide; A Cytostatic Agent.”Biochemical Pharmacology, vol. 26, pp. 1071-1075 (1977).
Perrin, et al., “HIV Treatment Failure: Testing for HIV Resistance in Clinical Practice.”Science AAAS, vol. 280, No. 5371, pp. 1871-1873 (1998).
Phelps, et al., “A Novel Basis for Capsid Stabilization by Antiviral Compounds.”J. Mol. Biol., vol. 254, pp. 544-551 (1995).
Tipples, et al., “Mutation in HBV RNA-Dependent DNA Polymerase Confers Resistance to Lamivudine In Vivo.”Hepatology, vol. 24, No. 3, pp. 714-717 (1996).
Keast et al. “Inhibition in vitro of the replication of murine cytomegalovirus or reovirus type 3 by the glutamine analogue acivicin.”Arch Virol. vol. 124, pp. 235-243 (1992).
Dobos. “Protein-Primed RNA Synthesis in vitro by the Virion-Associated RNA Polymerase of Infectious Pancreatic Necrosis Virus.”Virology. vol. 208, pp. 19-25 (1995).
Hudson et al. The efficacy of amantadine and other antiviral compounds against two salmonid viruses in vitro.Antiviral Research. vol. 9, pp. 379-385 (1988).
Hasobe et al. “Antiviral Activity and its mechanism of guanine 7-n-oxided on DNA and RNA viruses derived from salmonid.”J. of Antibiotics. vol. 38. No. 11, pp. 1581-1587. (1985).
Unknown. “ACIVICIN Antineoplastic.”Drugs of the Future. vol. 18, No. 4. pp. 362 (1993).
Gil-Fernandez et al. “Comparative efficacy of broad-spectrum antiviral agents as inhibitors of African swine fever virus replication in vitro.”Elsevier Science Publishers B.V. (Biomedical Division), pp. 151-160 (1986).
Smee et al. “Inhibition of Rotoviruses by selected antiviral substances: Mechanisms of viral inhibition and In vivo Activity.” vol. 21, No. 1. pp. 66-73 (1981).
Dobos et al. 1980 CA:18696.
Keast et al. 117CA:103654, 1992.
Hanka et al. 79CA:100631, 1984.
Martin et al. 82CA:132911, 1984.
Dobos. “Protien-Primed RNA Synthesis in Vitro by the Virion-Associated RNA Polymerase of Infectious Pancreatic Necrosis Virus.”Virology. vol. 208. pp. 19-25 (1995).
Dobos. “In Vitro Guanylylation of Infectious Pancreatic Necrosis Virus Polypeptide VPI.”Virology. vol. 193 pp. 403-413 (1993).
Hudson et al. “The efficacy of amantadine and other antiviral compounds against two salmonid viruses in vitro.”Antiviral Research. vol. 9. pp. 379-385 (1988).
Jashes et al. “Inhibitors of infectious pancreatic necrosis virus (IPNV) replication.”Antiviral Research. vol. 29. pp. 309-312 (1996).
Jashes et al. “Inhibitory effects of EICAR on infectious pancreatic necrosis virus replication.”Antiviral Researchvol. 45. pp. 9-17 (2000).
Keast et al. “Inhibition in vitro of the replication of murine cytomegalovirus or reovirus type 3 by the glutamine alaogue acivicin.”Archives of Virology. vol. 124. pp. 235244 (1992).
Mugus et al. “Effect of Ribavirin on the Replication of Infectious Pancreativ Necrosis Virus in Fish Cell Cultures.”J. of Gen. Virol. vol. 47. pp. 47-57 (1980).
Moya et al. “In vivo effect of EICAR (5-ethynyl-1-β-D-ribofuranosylimidazol-carboxamide) on experimental infected rainbow trouth (Oncorhynchus mykiss) and coho salmon (Oncorhynchus kisutch) fry with infectious pancreatic necrosis virus.”Antiviral Research. vol. 48. pp. 125-130 (2000).
Savan et al. Effect of virazole on rainbow trout Salmo gairdneri Richardson fry infected with infectious pancreatic necrosis virus.J. of Fish Diseases. vol. 3. pp. 437-440 (1980).
Woods et al. “In vitro and in vivo activities of WIN 54954, a new broad-spectrum antipicornavirus drug.”Antimicrob. Agents Chemother. vol. 33, No. 12. pp. 2069-2074 (1989).
Crane et al. “First isolation of an aquatic birnavirus from farmed and wild fish species in Australia.”Dis. Aquat. Organ. vol. 43. No. 1. pp. 1-14 (2000).
Blake et al. “Phylogentic relationships of aquatic birnaviruses based on deduced amino acid sequence of genome segment A cDNA”Dis. Aquat. Organ. vol. 45. No. 2. pp. 89-102 (2001).
Blake et al. “Detection and identification of aquatic birnaviruses by PCR assay.”J. of Clin. Mircrobiol. vol. 33. No. 4. pp. 835-839 (1995).
Balzarini et al. “Metabolizm of EICAR (5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide), a potent inhibitor of inosinate dehydrogenase.”Adv. Exp. Med. Biol. vol. 431. pp. 723-728 (1998).
Kitaoka et al. “Comparative efficacy of
Mlynarz Geraldine Z.
Sandino Ana Maria
Javanmard Sahar
Laboratorio de Diagnostico Gam S.A.
Merchant & Gould P.C.
Padmanabhan Sreeni
LandOfFree
Method for increasing the survival of aquatic and other... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for increasing the survival of aquatic and other..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for increasing the survival of aquatic and other... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4264099